How Does AbbVie Make its Money?
AbbVie is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription drugs across immunology, oncology, neuroscience, and aesthetics. The company was spun off from Abbott Laboratories in 2013 and quickly became one of the world’s largest pharma companies on the back of Humira — the best-selling drug in pharmaceutical history. As Humira loses patent protection to biosimilar competition, AbbVie is successfully transitioning to its next-generation immunology drugs Skyrizi and Rinvoq, while also building a large aesthetics franchise through its 2020 acquisition of Allergan (Botox).
AbbVie (ABBV) Business Model
AbbVie operates in the pharmaceuticals sector. Below is a summary of AbbVie’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from AbbVie’s 2024 fiscal year filings with the SEC.
AbbVie Competitors
AbbVie’s key competitors and comparable public companies in the pharmaceuticals sector include Eli Lilly, Pfizer, and Johnson & Johnson. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how AbbVie stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Product / Franchise | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Skyrizi | $11.7B | $7.8B | +50.0% |
| Rinvoq | $5.6B | $3.9B | +43.6% |
| Humira | $8.9B | $14.4B | -38.2% |
| Botox (Therapeutic + Cosmetic) | $5.8B | $5.5B | +5.5% |
| Juvederm / Aesthetics | $2.0B | $1.9B | +5.3% |
| Imbruvica | $2.8B | $3.6B | -22.2% |
| Vraylar | $3.1B | $2.6B | +19.2% |
| Other Products | $14.7B | $13.3B | +10.5% |
| Total Net Revenue | $54.6B | $53.0B | +3.0% |
Immunology — 48% of Revenue
Immunology is AbbVie’s largest and most important franchise. The story here is the Humira-to-Skyrizi/Rinvoq transition:
- Skyrizi ($11.7B) — Treats psoriasis, psoriatic arthritis, and Crohn’s disease. Growing 50% year-over-year and on track to become AbbVie’s top-selling drug. Peak sales estimates exceed $20B
- Rinvoq ($5.6B) — A JAK inhibitor treating rheumatoid arthritis, atopic dermatitis, ulcerative colitis, and Crohn’s disease. Growing 44% with significant label expansion remaining
- Humira ($8.9B) — Once generated $21B annually at peak. Revenue is declining rapidly due to U.S. biosimilar competition that launched in 2023, but the decline is being more than offset by Skyrizi + Rinvoq combined growth
The immunology transition is the defining financial story — Skyrizi + Rinvoq combined revenue of $17.3B already exceeds Humira, validating AbbVie’s pipeline strategy.
Aesthetics — 14% of Revenue
Acquired through the $63B Allergan deal in 2020:
- Botox Cosmetic (~$2.8B) — The world’s best-known injectable wrinkle treatment, with over 60% market share
- Botox Therapeutic (~$3.0B) — Treats chronic migraines, overactive bladder, and spasticity
- Juvederm (~$2.0B) — Dermal fillers for lip augmentation and facial contouring
Aesthetics growth has been modest as consumer discretionary spending normalized, but the franchise provides diversification and high margins.
Oncology — 10% of Revenue
- Imbruvica ($2.8B) — A BTK inhibitor for blood cancers. Declining due to competition from next-generation treatments
- Venclexta (~$2.5B) — Partnered with Roche for chronic lymphocytic leukemia. Stable and growing
- Elahere — Emerging ovarian cancer drug from the Immunomedics pipeline
Neuroscience — 9% of Revenue
- Vraylar ($3.1B) — An antipsychotic for bipolar disorder and schizophrenia, growing 19% and becoming a franchise drug
- Qulipta (~$1.0B) — A migraine prevention treatment gaining market share
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $54.6B | $53.0B |
| Cost of Revenue | $17.4B | $17.7B |
| Gross Profit | $37.2B | $35.3B |
| Operating Expenses | $20.1B | $19.8B |
| Operating Income | $17.1B | $15.5B |
| Net Income | $4.3B | $4.9B |
Key Financial Metrics
- Gross Margin: 68.1% — Strong pharmaceutical-grade margins reflecting the pricing power of patent-protected specialty drugs.
- Operating Margin: 31.3% — Solid, though compressed by heavy R&D investment ($8.5B) and commercialization costs for Skyrizi, Rinvoq, and newer launches.
- Revenue Growth: +3.0% — Modest headline growth masks the underlying story: Skyrizi/Rinvoq grew $5.6B combined while Humira declined $5.5B. The transition is essentially revenue-neutral in 2024, with growth accelerating from here.
- Net Income: $4.3B — Lower than operating income suggests due to $10B+ in amortization charges related to the Allergan acquisition. Adjusted earnings (which exclude acquisition accounting) are closer to $14B+.
Is AbbVie Profitable?
Yes, AbbVie is profitable. The company reported net income of $4.3B on total revenue of $54.6B. Note that GAAP net income is significantly depressed by ~$10B in annual amortization from the Allergan acquisition. On an adjusted basis, AbbVie’s earnings power is approximately $14-15B. With a gross margin of 68.1%, AbbVie demonstrates strong pharmaceutical-sector profitability.
Where Does AbbVie Spend its Money?
- Cost of Goods Sold (~$17.4B): Manufacturing, distribution, and royalty costs for its drug portfolio. Includes milestone and royalty payments to licensing partners.
- R&D (~$8.5B): Drug discovery, clinical trials, and regulatory submissions. AbbVie has 90+ compounds in its pipeline across immunology, oncology, neuroscience, and eye care.
- SG&A (~$11.6B): Sales force (thousands of reps calling on doctors), marketing, patient access programs, and corporate overhead.
- Intangible Amortization (~$10.5B): Non-cash charges from the Allergan acquisition. This is the single largest reason GAAP net income appears lower than economic earnings.
- Dividends (~$10.4B): AbbVie is a Dividend Aristocrat with 52 consecutive years of dividend increases (counting the Abbott legacy). The ~3.5% yield attracts income-focused investors.
What to Watch
- Skyrizi/Rinvoq trajectory — These two drugs are expected to generate $27B+ combined by 2027. If they hit peak sales estimates of $30B+, AbbVie’s revenue growth reaccelerates meaningfully after the Humira trough.
- Humira erosion curve — Biosimilar uptake in the U.S. will determine how fast Humira declines. A steeper decline creates a larger near-term revenue headwind but is already priced in by most analysts.
- Pipeline catalysts — Key pipeline assets include emraclidine (schizophrenia), ABBV-400 (solid tumors), and tavapadon (Parkinson’s). Late-stage readouts over the next 2 years could add significant long-term value.
- Aesthetics recovery — Botox and Juvederm growth slowed in 2023-2024 amid consumer spending normalization. A return to mid-to-high single digit growth would improve the overall revenue mix.
- Allergan amortization roll-off — The $10B+ annual amortization charge will step down meaningfully starting in 2027-2028, causing GAAP earnings to converge closer to adjusted earnings and potentially driving a share price re-rating.
AbbVie (ABBV) Financial Summary
AbbVie (ABBV) is a pharmaceuticals company that generated $54.6B in total net revenue in fiscal year 2024. Revenue grew +3.0% year-over-year. The company earned $4.3B in GAAP net income (~$14B+ adjusted), making it highly profitable. For a deeper look at AbbVie’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.